A class of kinases are particularly promiscuous binders of small molecule inhibitors. Using combined biomolecular simulations and biochemical studies, we show that the promiscuity of DDR1, one of the major members of this class, is likely due to an unusually stable DFG-out conformation.
Kevin Hauser, Christopher Negron, Steven K. Albanese, Soumya Ray, Thomas Steinbrecher, Robert Abel, John D. Chodera, and Lingle Wang.
Communications Biology 1:70, 2018 [DOI] [PDF] [input files and analysis scripts]
In our first collaborative paper with Schrödinger, we present the first comprehensive benchmark assessing the ability for alchemical free energy calculations to predict clinical mutational resistance or susceptibility to targeted kinase inhibitors using the well-studied kinase Abl, the target of therapy for chronic myelogenous leukemia (CML).
Yosi Shamay, Janki Shah, Mehtap Işık, Aviram Mizrachi, Josef Leibold, Darjus F. Tschaharganeh, Daniel Roxbury, Januka Budhathoki-Uprety, Karla Nawaly, James L. Sugarman, Emily Baut, Michelle R. Neiman, Megan Dacek, Kripa S. Ganesh, Darren C. Johnson, Ramya Sridharan, Karen L. Chu, Vinagolu K. Rajasekhar, Scott W. Lowe, John D. Chodera, and Daniel A. Heller.
Nature Materials 17:361, 2018. [DOI] [PDF] [Supporting Info] [nano-drugbank]
In a collaboration with the Heller Lab at MSKCC, we show how indocyanine nanoparticles can package insoluble selective kinase inhibitors with high mass loadings and efficiently deliver them to tumors.